Giulio Barteselli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giulio Barteselli has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Jay Chhablani
UPMC Eye Center, University of Pittsburgh, Pittsburgh, Pennsylvania
14 shared publications - William R. Freeman
Department of Ophthalmology, Jacobs Retina Center at the Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.
14 shared publications - Francesco Viola
Department of Clinical Science and Community Health, University of Milan, Milan, Italy
13 shared publications - Sharif El-Emam
Ophthalmology Department, Faculty of Medicine, Tanta University, Tanta, Egypt
12 shared publications Dirk-Uwe Bartsch
Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, California; and
11 shared publicationsLingyun Cheng
Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, California, USA
10 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Elsevier in Ophthalmology
Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase III SatraGO-1 and SatraGO-2 Randomized Trials
- 7 September 2026
- Published by Elsevier in Ophthalmology
Open AccessEfficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase III SatraGO-1 and SatraGO-2 Randomized Trials
- Open Access
- 25 February 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (8) , 767-773
Macular Atrophy-Related Observations in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial
- 25 February 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (8) , 767-773
Open AccessMacular Atrophy-Related Observations in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial
- Open Access
- 2 March 2023
- Published by Elsevier in Ophthalmology
- Vol. 130 (7) , 735-747
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results
- 2 March 2023
- Published by Elsevier in Ophthalmology
- Vol. 130 (7) , 735-747
Open AccessArchway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results
- Open Access
- 16 May 2022
- Published by Elsevier in Ophthalmology Retina
- Vol. 6 (11) , 1028-1043
Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab
- 16 May 2022
- Published by Elsevier in Ophthalmology Retina
- Vol. 6 (11) , 1028-1043
Open AccessManagement of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab
- Open Access
- 2 May 2022
- Published by Taylor & Francis in Drug Delivery
- Vol. 29 (1) , 1326-1334
The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery
The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond. The PDS includes an ocular implant, a customized formulation of ranibizumab, and four dedicated ancillary devices for initial fill, surgical implantation, refill-exchange, and explantation, if clinically indicated. Ranibizumab is an ideal candidate for the PDS on account of its unique physicochemical stability and high solubility. Controlled release is achieved via passive diffusion through the porous release control element, which is tuned to specific drug characteristics to accomplish a therapeutic level of ranibizumab in the vitreous. To characterize drug release from the implant, release rate was measured in vitro with starting concentrations of ranibizumab 10, 40, and 100 mg/mL, with release of ranibizumab 40 and 100 mg/mL found to remain quantifiable after 6 months. Using a starting concentration of 100 mg/mL, active release rate at approximately 6 months was consistent after the initial fill and first, second, and third refills, demonstrating reproducibility between implants and between multiple refill-exchanges of the same implant. A refill-exchange performed with a single 100-µL stroke using the refill needle was shown to replace over 95% of the implant contents with fresh drug. In vitro data support the use of the PDS with fixed refill-exchange intervals of at least 6 months in clinical trials.
- 2 May 2022
- Published by Taylor & Francis in Drug Delivery
- Vol. 29 (1) , 1326-1334
Open AccessThe Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery
The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond. The PDS includes an ocular implant, a customized formulation of ranibizumab, and four dedicated ancillary devices for initial fill, surgical implantation, refill-exchange, and explantation, if clinically indicated. Ranibizumab is an ideal candidate for the PDS on account of its unique physicochemical stability and high solubility. Controlled release is achieved via passive diffusion through the porous release control element, which is tuned to specific drug characteristics to accomplish a therapeutic level of ranibizumab in the vitreous. To characterize drug release from the implant, release rate was measured in vitro with starting concentrations of ranibizumab 10, 40, and 100 mg/mL, with release of ranibizumab 40 and 100 mg/mL found to remain quantifiable after 6 months. Using a starting concentration of 100 mg/mL, active release rate at approximately 6 months was consistent after the initial fill and first, second, and third refills, demonstrating reproducibility between implants and between multiple refill-exchanges of the same implant. A refill-exchange performed with a single 100-µL stroke using the refill needle was shown to replace over 95% of the implant contents with fresh drug. In vitro data support the use of the PDS with fixed refill-exchange intervals of at least 6 months in clinical trials.
- Open Access
- 12 April 2022
- Published by Elsevier in Ophthalmology Retina
- Vol. 6 (9) , 786-795
Prevalence and Progression of Macular Atrophy in Eyes with Neovascular Age-Related Macular Degeneration in the Phase 2 Ladder Trial of the Port Delivery System with Ranibizumab
- 12 April 2022
- Published by Elsevier in Ophthalmology Retina
- Vol. 6 (9) , 786-795
Open AccessPrevalence and Progression of Macular Atrophy in Eyes with Neovascular Age-Related Macular Degeneration in the Phase 2 Ladder Trial of the Port Delivery System with Ranibizumab
- Top Cited PapersOpen Access
- 1 March 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (3) , 295-307
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- 1 March 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (3) , 295-307
Top Cited PapersOpen AccessArchway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- 20 July 2021
- Published by Royal Society of Chemistry (RSC)
- p. 76-89
CHAPTER 4. Sustained Delivery of Ocular Protein Therapeutics
Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in older adults in the United States and is primarily driven by vascular endothelial growth factor A (VEGF-A). While currently approved anti-VEGF therapies have revolutionized the treatment of nAMD, they require frequent intravitreal injections to maintain vision. This dosing regimen creates an enormous treatment burden on patients, thereby leading to less overall patient adherence and sub-optimal outcomes in the real-world setting. Therefore, there is a current unmet need for durable anti-VEGF treatments. The Port Delivery System with ranibizumab (PDS) is an investigational, innovative technological advance that enables continuous delivery of a customized formulation of ranibizumab to optimize visual outcomes while reducing the treatment burden. Here, we highlight the development of the Port Delivery System, long-term stability of ocular therapeutics, and their suitability for the Port Delivery System, as well as preclinical and clinical studies leading to first-in-human validation of this transformative delivery modality. The PDS may offer flexibility and options for prolonged treatment intervals in ophthalmology.
- 20 July 2021
- Published by Royal Society of Chemistry (RSC)
- p. 76-89
CHAPTER 4. Sustained Delivery of Ocular Protein Therapeutics
Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in older adults in the United States and is primarily driven by vascular endothelial growth factor A (VEGF-A). While currently approved anti-VEGF therapies have revolutionized the treatment of nAMD, they require frequent intravitreal injections to maintain vision. This dosing regimen creates an enormous treatment burden on patients, thereby leading to less overall patient adherence and sub-optimal outcomes in the real-world setting. Therefore, there is a current unmet need for durable anti-VEGF treatments. The Port Delivery System with ranibizumab (PDS) is an investigational, innovative technological advance that enables continuous delivery of a customized formulation of ranibizumab to optimize visual outcomes while reducing the treatment burden. Here, we highlight the development of the Port Delivery System, long-term stability of ocular therapeutics, and their suitability for the Port Delivery System, as well as preclinical and clinical studies leading to first-in-human validation of this transformative delivery modality. The PDS may offer flexibility and options for prolonged treatment intervals in ophthalmology.
- 18 November 2020
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 49 (3) , 663-672
Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration
The Port Delivery System with ranibizumab (PDS) is an investigational drug delivery system designed to provide continuous intravitreal release of ranibizumab for extended durations. The PDS consists of a permanent, surgically placed, refillable intraocular implant; a customized formulation of ranibizumab; and ancillary devices to support surgery and refill procedures. A toxicology program was conducted to evaluate the ocular toxicology and biocompatibility of the PDS to support its clinical development program and product registrational activities. PDS safety studies included a 6-month chronic toxicology evaluation in minipigs as well as evaluation of nonfunctional surrogate implants (comprised of the same implant materials but without ranibizumab) in rabbits. Biocompatibility of the implant and ancillary devices was evaluated in both in vitro and in vivo studies. Implants and extracts from implants and ancillary devices were nongenotoxic, noncytotoxic, nonsensitizing, and nonirritating. Ocular findings were comparable between implanted and sham-operated eyes, and no systemic toxicity was observed. The results of this nonclinical toxicology program demonstrated that the PDS was biocompatible and that intravitreal delivery of ranibizumab via the PDS did not introduce any new toxicology-related safety concerns relative to intravitreal injections, supporting ongoing PDS clinical development and product registrational evaluation.
- 18 November 2020
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 49 (3) , 663-672
Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration
The Port Delivery System with ranibizumab (PDS) is an investigational drug delivery system designed to provide continuous intravitreal release of ranibizumab for extended durations. The PDS consists of a permanent, surgically placed, refillable intraocular implant; a customized formulation of ranibizumab; and ancillary devices to support surgery and refill procedures. A toxicology program was conducted to evaluate the ocular toxicology and biocompatibility of the PDS to support its clinical development program and product registrational activities. PDS safety studies included a 6-month chronic toxicology evaluation in minipigs as well as evaluation of nonfunctional surrogate implants (comprised of the same implant materials but without ranibizumab) in rabbits. Biocompatibility of the implant and ancillary devices was evaluated in both in vitro and in vivo studies. Implants and extracts from implants and ancillary devices were nongenotoxic, noncytotoxic, nonsensitizing, and nonirritating. Ocular findings were comparable between implanted and sham-operated eyes, and no systemic toxicity was observed. The results of this nonclinical toxicology program demonstrated that the PDS was biocompatible and that intravitreal delivery of ranibizumab via the PDS did not introduce any new toxicology-related safety concerns relative to intravitreal injections, supporting ongoing PDS clinical development and product registrational evaluation.
- Top Cited PapersOpen Access
- 1 August 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (8) , 1141-1154
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- 1 August 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (8) , 1141-1154
Top Cited PapersOpen AccessThe Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration